What the scenese drug is all about and what it treatment it is used for.FDA update

1. Clinuvel and the FDA approval for SCENESSE
A sixty percent rise on the Australian stock market (ASX)is a huge spikeadn that is what happened
today. Its th new FDA approved drug called SCENESSE®
clinuvel.com
Stock price: CUV (ASX) $45.00 +16.91 (+60.20%)
Clinuvel was formerly Australian startup called Epitan, which changed its name to Clinuvel in
2006.
Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing
drugs for the treatment of a range of severe skin disorders.
Here is the clinuvel update released today at afr
http://member.afraccess.com/media?id=CMN://3A478020&filename=20170919/CUV_01897356.
pdf
So what is SCENESSE®
The scenesse drug will assist with treatment for a disorder erythropoietic protoporphyria.
CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg drug targeting erythropoietic
protoporphyria (EPP), has completed Phase II and III trials in the US and Europe.
Scenesse is approved in Europe for the treatment of porphyria, a disease in which patients are
very sensitive to sunlight, and it works by making the skin darker through a process similar to
tanning, but without exposure to the sun. some countries still have a ban on this treatment and
drug
From Wikipedia (interesting facts)
Very early in the process one of the scientists, who was conducting experiments on himself with
an early tool compound, melanotan II, injected himself with twice the dose he intended and got
an eight-hour erection, along with nausea and vomiting. Scenesse is available in Germany,
Austria, the Netherlands, Italy and Switzerland
An estimated 45 million patients worldwide suffer from light-sensitive skin disorders that make
them potential candidates for SCENESSE. More here
http://www.australianpennystocks.com/stock-price/why-clinuvel-stock-price-has-risen-60-in-
one-day/